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Abstract
Rationale Premature discontinuation of antidepressant drugs
is a frequent clinical problem. Adverse effects are common,
occur early on in treatment and are reported to be one of the
main reasons for discontinuation of antidepressant treatment.
Objectives To investigate the association between adverse
effects occurring in the first 2 weeks of antidepressant treat-
ment and discontinuation by 6 weeks as the outcome. To
investigate the time profile of adverse effects induced by the
selective serotonin reuptake inhibitor citalopram and the nor-
adrenaline reuptake inhibitor reboxetine over 12 weeks of
treatment.
Methods Six hundred and one depressed individuals were
randomly allocated to either citalopram (20 mg daily) or
reboxetine (4 mg twice daily). A modified version of the
Toronto Side Effects Scale was used to measure 14 physical
symptoms at baseline (medication free) and at 2, 6 and
12 weeks after randomisation.
Results Individuals randomised to reboxetine reported a
greater number of adverse effects and were more likely to
stop treatment than individuals receiving citalopram.
Dizziness (OR 1.83; 95% CI 1.09, 3.09; p=0.02) and the total
number of adverse effects (OR 1.12; 95% CI 1.00, 1.25; p=
0.06) reported at 2 weeks were associated with discontinua-
tion from overall antidepressant treatment by 6 weeks.
Reports of adverse effects tended to reduce throughout the
12 weeks for both antidepressants.
Conclusions The majority of adverse effects were not indi-
vidually associated with discontinuation from antidepressant
treatment. Reports of physical symptoms tended to reduce
over time. The physical symptoms that did not reduce over
time may represent symptoms of depression rather than
antidepressant-induced adverse effects.
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Introduction
Depression is a chronic disorder affecting a relatively high
proportion of individuals each year (Wittchen et al. 2011).
Long-term treatment is necessary to alleviate the symptoms of
depression. Antidepressants are effective at treating depres-
sion, but discontinuation rates are high (Dunn et al. 1999).
Adverse effects occur frequently with antidepressant medica-
tion (Cramer and Rosenheck 1998), especially early in
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treatment (Bull et al. 2002), and are reported as a common
reason for early discontinuation from antidepressant therapy
(Demyttenaere et al. 2001).
Selective serotonin reuptake inhibitors (SSRIs) are the
most commonly prescribed antidepressants in the UK, and
citalopram accounted for over half of all SSRI prescriptions in
2011 (13.5 million prescriptions) (NHS 2011). Despite their
superior adverse effect profile compared with the older gen-
eration of tricyclic antidepressants (TCAs), SSRIs frequently
cause gastrointestinal adverse effects, insomnia, headache,
anxiety and sexual dysfunction (Goldstein and Goodnick
1998; Ferguson 2001a). TCAs are less well tolerated than
either SSRIs or selective noradrenaline reuptake inhibitors
(NARIs) potentially due to their broader pharmacologic
mechanism of action (Anderson 2000). NARIs act specifically
via the noradrenaline transporter, leading to an increase in
synaptic noradrenaline. Reboxetine was the first NARI to be
licenced in the UK and accounted for just 0.1 % of the total
annual prescriptions in 2011 (NHS 2011). It has been reported
that reboxetine is less well tolerated than citalopram and can
induce adverse effects such as dry mouth, constipation, in-
creased sweating and hot flushes (Hajos et al. 2004; Cipriani
et al. 2009; Eyding et al. 2010).
Previous studies have reported rates of discontinuation of
antidepressant medication ranging from 33 to 53 % with
adverse effects cited as the reason for 23–36 % of discontinu-
ations (Demyttenaere et al. 2001; Hu et al. 2004). Others have
reported more discontinuations among individuals randomised
to reboxetine than to citalopram (49% vs. 31% for citalopram)
(Langworth et al. 2006), and adverse effects were cited more
frequently as the reason for discontinuation from reboxetine
(40 % vs. 17 % for citalopram) (Langworth et al. 2006).
There are fewer data onwhether specific adverse effects are
associated with discontinuation from antidepressant treat-
ment. In the genome-based therapeutic drugs for depression
(GENDEP) study, 811 adults with moderate to severe unipolar
depression were either randomised to receive escitalopram
(SSRI) or nortriptyline, or, if contraindications for one of the
drugs were present, allocated non-randomly to the other anti-
depressant. Nortriptyline is a TCA that predominantly inhibits
noradrenaline reuptake. The authors reported evidence that
urinary problems, dryness of mouth, blurred vision and ortho-
static dizziness, as well as the total number of adverse effects
reported, were associated with discontinuation from overall
antidepressant treatment (Uher et al. 2009a).
Several studies have reported that adverse effects progres-
sively decrease over time as the person continues to take the
medication (Greist et al. 2004; Uher et al. 2009a). The
evidence-based guidelines for treating depressive disorders
with antidepressants, compiled by the British Association for
Psychopharmacology (BAP), report that adverse effects tend
to improve over time; moreover, some of these effects (such as
nausea on SSRIs) are usually short-lived while others (such as
anticholinergic adverse effects on TCAs) appear to be more
resilient (Anderson et al. 2008). Since physical symptoms are
common in depression, the identification of adverse effects
requires judgement on the part of the patient (Haug et al.
2004).
We report on the adverse effect profile following treatment
with citalopram or reboxetine over a 12-week period. We
investigated how reports of specific adverse effects changed
over the 12 weeks of treatment. In addition, we examined
whether adverse effects occurring early during the course of
antidepressant treatment (in the first 2 weeks) are associated
with discontinuation of medication.
Methods
The GENPOD trial
The trial methods have been reported in detail elsewhere
(Thomas et al. 2008). In brief, the study was a multicentre,
randomised controlled trial (RCT) conducted in three UK
centres (Bristol, Birmingham and Newcastle) in which pa-
tients with depression, recruited in primary care, were ran-
domly allocated to receive either citalopram (20 mg daily) or
reboxetine (4 mg twice daily). The genetic and clinical pre-
dictors of treatment response in depression (GENPOD) trial
were designed to test two primary hypotheses regarding ge-
netic and clinical predictors of response to antidepressant
medication (Lewis et al. 2011; Wiles et al. 2012). Secondary
analysis of these trial data can nevertheless provide informa-
tion on the adverse effect profile of these two antidepressants.
Eligible participants were those aged 18–74 years who had
already agreed with their general practitioner (GP) that an
antidepressant should be prescribed. Patients who had taken
antidepressant medication within the 2 weeks prior to the
baseline assessment and those who could not complete self-
administered questionnaires were excluded. GPs also exclud-
ed those with medical contraindications to antidepressant
medication, those who had a history of psychosis, bipolar
affective disorder, major substance or alcohol misuse and
others whose participation was deemed inappropriate. At the
baseline assessment, only patients with depression that ful-
filled the ICD-10 criteria for depression (category F32),
assessed using computerised Clinical Interview Schedule—
revised version (CIS-R) (Lewis et al. 1992; WHO 1992;
Lewis 1994), and a Beck Depression Inventory (BDI) (Beck
et al. 1961) score above 14, were eligible to participate in the
study.
Randomisation procedure
Following the baseline assessment, eligible patients
were asked to provide written informed consent for trial
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participation. Randomisation was conducted using a
computer-generated code, administered centrally and commu-
nicated by telephone and thereby concealed in advance from
the researcher. Allocation was stratified by severity of depres-
sive symptoms (CIS-R total score ≥28 or <28) and by centre,
using variable block sizes to maximise concealment. The
researcher gave the randomised medication to the participant.
Those randomly allocated to reboxetine were advised to begin
with a dose of 2 mg twice daily and increase it to 4 mg twice
daily after about 4 days. Individuals randomised to citalopram
received 20mg daily. All patients were advised that they could
approach their GP if they wished to increase the dose of their
allocated treatment. Patients, GPs and researchers were not
blinded to treatment allocation.
Measures
Self-reported outcome data on physical symptoms were col-
lected at baseline and at 2, 6 and 12 weeks after
randomisation. Data were collected over the telephone at
2 weeks and by means of a self-administered questionnaire
at baseline, 6 and 12weeks. Amodified version of the Toronto
Side Effects Scale (Vanderkooy et al. 2002) was used to
measure 14 physical symptoms (Supplementary Figure 1).
Individuals reported the number of days that they had experi-
enced each physical symptom in the last week (0, 1–3, 4–
7 days). A measure of baseline physical symptoms was re-
quired in order to identify the occurrence of adverse effects
(physical symptoms induced by antidepressant treatment),
rather than residual symptoms of depression. Physical symp-
toms reported at 2, 6 and 12 weeks will be referred to as
adverse effects from this point on. Participants were only
asked about the presence and frequency of physical symptoms
and were not asked whether the symptom was caused by the
antidepressant. Discontinuation of antidepressant medication
was assessed at 6 and 12 weeks by self report. Adherence to
medication was also assessed at 6 weeks by a pill count of
returned medication.
Statistical analysis
Data were analysed using Stata version 12.1 (StataCorp
2011). In preliminary analyses, relatively few individuals
reported suffering from the adverse effects for four or more
days in the previous week; therefore, data on individual ad-
verse reactions were collapsed into dichotomous variables
(present/absent) for further analyses. A measure of general
adverse effect burden was derived from the number of adverse
effects reported at each time point and treated as a continuous
variable (not including the male-specific questions). All anal-
yses were adjusted for physical symptoms reported at baseline
(medication free) so that only adverse effects induced by
citalopram or reboxetine were investigated.
To investigate whether the two antidepressants had dis-
tinct adverse effect profiles, we compared reports of adverse
effects between individuals allocated to citalopram and
reboxetine at 2, 6 and 12 weeks after randomisation using
random effects logistic or linear regression models to ac-
count for repeated measurements for each individual.
Summary odds ratios (OR), 95 % confidence intervals
(95 % CI) and p values were reported. We formally evalu-
ated the appropriateness of this summary measure by in-
cluding an interaction term between time and randomised
treatment.
Random effects logistic (for individual adverse effects) and
linear (for the number of adverse effects reported) regression
models using data from 0 to 2 weeks in a repeated measures
model were used to examine whether reports of physical
symptoms increased from baseline (medication free) to
2 weeks after receiving treatment. Random effects logistic
and linear regression models using data from 2, 6 and
12 weeks in a repeated measures model were used to examine
whether the reporting of adverse effects changed over the
12 weeks. We investigated the effect of time in these models,
as described earlier.
Logistic regression models were used to investigate wheth-
er adverse effects at 2 weeks are associated with discontinu-
ation from antidepressant treatment by 6 weeks. We investi-
gated whether the impact of the adverse effect varied by
treatment group by including an interaction term between
adverse effect and randomised treatment.
As has been reported previously (Wiles et al. 2012), indi-
viduals lost to follow-up at 6 weeks were younger and report-
ed more life events at baseline. The impact of missing data on
our findings was investigated by adjusting for these factors in
the various regression models. This method should address
any bias under a missing at random assumption (Carpenter
and Kenward 2013). Sensitivity analyses were conducted in
the subset of those individuals who adhered to treatment. All
models were adjusted for the trial ‘design’ (stratification)
variables (severity of baseline depression (CIS-R score <28
and≥28) and recruitment centre) and, where appropriate,
treatment allocation.
Results
Trial participation and follow-up
A comparison of the randomised groups at baseline and the
CONSORT flow chart for the GENPOD trial has previously
been published (Lewis et al. 2011). In total, 601 participants
(68 % female, n=408) were randomised to receive either
citalopram (n=298) or reboxetine (n=303). The average par-
ticipant was aged 38.8 years (sd 12.4) with a baseline BDI
score of 33.7 (sd 9.7) and CIS-R score of 30.8 (sd 8.0).
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Fifty six participants randomised to citalopram had their
daily dose increased from 20 mg to 30 mg (n=11), 40 mg (n=
33) and 60 mg (n=11) (one further participant had an increase
in the prescribed dose of an unknown amount). Thirteen of
those allocated to reboxetine had their daily dose increased to
10 mg (n=3), 12 mg (n=9) and 16 mg (n=1). Ninety-six
percent (n=576) completed the 2-week follow-up (citalopram
n=284, reboxetine n=292), 91 % (n=546) completed the 6-
week follow-up (citalopram n=274, reboxetine n=272) and
81 % (n=486) completed the 12-week follow-up (citalopram
n=253, reboxetine n=233).
Data completeness
For the majority of adverse effects, there were complete data
in over 99 % of the individuals followed up. There was a
greater amount of missing data for the questions relating to
male-specific adverse effects. For the question referring to
difficulty with ejaculation, 75 % (n=145) of males had com-
plete data at baseline, 81 % (n=150) at 2 weeks, 86 % (n=
149) at 6 weeks and 84 % (n=123) at 12 weeks. Similarly, for
impotence, 80% (n=154) had complete data at baseline, 86%
(n=160) at 2 weeks, 86 % (n=149) at 6 weeks and 85 % (n=
124) at 12 weeks.
Discontinuation from antidepressant treatment
A greater proportion of individuals discontinued treatment
from reboxetine than citalopram (53 % vs. 31 %, p<0.001)
over the 12 weeks. Thirteen percent (n=77) of all individuals
discontinued antidepressant treatment by the 2-week
follow-up (citalopram n=27, reboxetine n=50), 26 %
(n = 159) discont inued by the 6-week fol low-up
(citalopram n=51, reboxetine n=108) and 42 % (n=
255) discontinued by the 12-week follow-up (citalopram
n=93, reboxetine n=162). The most common reason for
discontinuation was due to adverse effects reported by 61 %,
57 % and 43 % of individuals who discontinued at 2, 6 and
12 weeks, respectively.
Frequencies of adverse effects and drug comparisons
The majority of adverse effects reported at 2 weeks were
actually less common than reports of the physical symptoms
at baseline (when individuals were not taking an antidepres-
sant, ‘medication free’) (Supplementary Table 4). For exam-
ple, an individual had 32 % lower odds of reporting tremor
after 1 week of treatment compared to baseline (OR 0.68, 95%
CI 0.58, 0.81; p<0.001). However, individuals randomised to
reboxetine reported dry mouth, constipation and flushing, as
well as impotence and problems with ejaculation for males,
more commonly at 2 weeks than at baseline. There was also
some evidence to suggest that males randomised to citalopram
reported problems with ejaculation more commonly at
2 weeks than at baseline. When analysis was restricted to only
include individuals who adhered to treatment or included
factors associated with missing data in the regression model,
the results were consistent with the main analysis (data not
shown).
The proportion of individuals reporting each physical
symptom at baseline and each adverse effect at 2, 6 and
12 weeks after randomisation can be seen graphically in
Fig. 1, and the exact figures for those allocated to citalopram
in Supplementary Table 1 and to reboxetine in Supplementary
Table 2. The most frequently reported adverse effects amongst
those allocated to citalopram were daytime drowsiness (71 %
(n=193) of individuals after 6 weeks) and difficulty sleeping
(68 % (n=186) of individuals after 6 weeks). The most fre-
quently reported adverse effects amongst those allocated to
reboxetine were dry mouth, which was reported by 78 % (n=
228) of individuals after 2 weeks, and difficulty sleeping,
which was reported by 74 % (n=200) of participants after
6 weeks.
On average, the number of adverse effects reported by
individuals randomised to reboxetine was 5.6, 6.1 and 4.9 at
2, 6 and 12 weeks, respectively. Fewer adverse effects were
reported in the citalopram group (4.5, 5.2 and 4.3 adverse
effects reported at the same time points) (Supplementary
Tables 1 and 2).
To investigate whether the two antidepressants have dis-
tinct adverse effect profiles, we compared reports of adverse
effects between individuals allocated to citalopram and
reboxetine at 2, 6 and 12 weeks after randomisation in a
repeated measures analysis (Table 1). Nine of the 14 adverse
effects were more commonly reported during treatment with
reboxetine. The odds of reporting constipation, over the
12 weeks of treatment, were six times higher for individuals
receiving reboxetine than citalopram. Only diarrhoea and
daytime drowsiness were less commonly reported with
reboxetine treatment, with no evidence of a difference in
reports of tremor, nausea or difficulty ejaculating.
For two of the adverse effects, and for the total number of
adverse effects reported, there was evidence that the effect of
the treatment varied with time (p value for interaction between
treatment allocation and time is <0.05) (Table 2). There was a
weaker evidence of an interaction between treatment alloca-
tion and time for a further four adverse effects (p value<0.1).
In all cases, the effect of the drug on adverse effects was less
pronounced at 12 weeks than at 2 weeks. For example, on
average, individuals allocated to reboxetine reported one more
adverse effect at 2 weeks (OR 1.08, 95% CI 0.72, 1.45;
p<0.001) but only 0.4 more at 12 weeks (OR 0.41, 95% CI
−0.06, 0.88; p=0.08) compared to individuals allocated to
citalopram. The time-specific ORs or coefficients at 2, 6 and
12 weeks for these seven outcomes are reported in
Supplementary Table 3.
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Time course of adverse effects
Collection of data at baseline and 2, 6 and 12 weeks after
randomisation to medication allowed us to determine the time
course of adverse effects over the treatment period. Reports of
seven adverse effects (tremor, dry mouth, constipation, dizzi-
ness, hot flushes, impotence, difficulty ejaculating), as well as
the number of adverse effects reported, reduced over the
12weeks for both antidepressants (Table 2). There was aweaker
evidence that nausea was also reported less frequently with time.
Reports of agitation, difficulty sleeping, drowsiness and rapid
heartbeat initially increased between 2 and 6 weeks and then
decreased from 6 to 12 weeks (Fig. 1). There was a difference in
how reports of sweating (p value for interaction between time
and treatment, p=0.02), dizziness (p=0.02) and diarrhoea (p=
0.05) changed over the 12 weeks for the two antidepressants.
Reports of sweating only reduced over time for individuals
receiving reboxetine, while reports of diarrhoea only reduced
for individuals receiving citalopram (Table 2). For example, the
odds of reporting diarrhoea in the citalopram group decreased by
5 % for every week that passed (OR 0.95, 95% CI 0.91, 1.00),
while in the reboxetine group, they did not (OR 1.04, 95% CI
0.97, 1.11). When analysis was restricted to individuals who
adhered to treatment, the results were not substantially different
(Supplementary Table 5).
Are adverse effects reported at 2 weeks associated
with discontinuation by 6 weeks?
There was evidence of an association between antidepressant-
induced dizziness reported at 2 weeks and discontinuation of
antidepressant treatment by 6 weeks (OR 1.83, 95% CI 1.09,
3.09; p=0.02). There was also evidence that every additional
adverse effect reported at 2 weeks was associated with a 12 %
higher odds of discontinuation by 6 weeks (OR 1.12, 95% CI
1.00, 1.25; p=0.06). There was no evidence of an association
between any other adverse effect and discontinuation
(Table 3). Additionally, there was no evidence that the impact
Fig. 1 Plots showing proportion of individuals reporting each adverse
effect and the mean number of adverse effects over the 12-week trial
period. Plots show the proportion of individuals reporting each adverse
effect at baseline and at 2, 6 and 12 weeks after randomisation to
citalopram or reboxetine. The solid line represents individuals receiving
citalopram. The dashed line represents individuals receiving reboxetine.
The plots for difficulty ejaculating and impotence show the proportion of
men who reported these adverse effects. The plot ‘number of adverse
effects’ shows the mean number of adverse effects
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of the adverse effect on discontinuation was different between
the two treatment groups (interaction term between adverse
effect and randomised treatment, p>0.1). However, the results
stratified by treatment are available in Supplementary Table 6.
When the analysis was restricted to only include individuals
who adhered to treatment at 2 weeks or included factors
associated with missing data, the results were consistent with
the main analysis (data not shown).
Discussion
Main findings
To our knowledge, GENPOD is the largest RCT of depressed
individuals receiving the pharmacologically different antide-
pressants, citalopram and reboxetine. The adverse effects report-
ed by individuals in GENPOD are largely in agreement with the
adverse effect profiles previously reported (Ferguson 2001a;
Hajos et al. 2004; Langworth et al. 2006). Additionally, partic-
ipants allocated to receive reboxetine reported a greater number
of adverse effects and were more likely to discontinue antide-
pressant treatment. The impact of adverse effects on discontin-
uation was the same for both antidepressants, and only reports of
antidepressant-induced dizziness were associated with increased
odds of discontinuation by 6 weeks. Reports of the majority of
physical symptoms were more common at baseline (medication
free) than reports of adverse effects when on medication. In
general, reports of adverse effects tended to reduce throughout
the 12 weeks.
Strengths and limitations
The main strengths of the study are the large sample size and
the high follow-up rates (91 % at 6 weeks). Nevertheless, even
a small amount of missing data has the potential to introduce
bias. However, adjustment for factors associated with missing
data produced results consistent with our main analysis.
Additionally, we were able to assess the effect of adherence
by restricting analyses to include only the individuals who
were taking their medication. Assessing adherence by self
report is not the most accurate method; however, it is likely
that any errors would be the same in both treatment groups
resulting in a loss of precision, but not a source of bias.
Different methodologies were used to record physical
symptom data over the course of the trial potentially con-
founding our results. Data were collected over the telephone
at 2 weeks and by means of a self-administered questionnaire
at baseline, 6 and 12 weeks. However, the comparison of face-
to-face and telephone assessments for mental health measures
has suggested that the mode of administration does not intro-
duce any bias (Evans et al. 2004).
Table 1 Summary odds ratios or linear regression coefficient of reporting adverse effects amongst those allocated to receive reboxetine compared with
those allocated to receive citalopram from a repeated measures analysis at 2, 6 and 12 weeks
Adverse Effect N OR 95 % CI p value p value for interaction between
treatment and time
Tremor 1,608 0.99 0.63, 1.58 0.98 0.12
Agitation 1,607 1.76 1.33, 2.33 <0.001 0.28
Dry mouth 1,603 3.33 2.25, 4.91 <0.001 0.09
Excessive sweating 1,607 1.89 1.33, 2.69 <0.001 0.02
Constipation 1,606 6.09 3.76, 9.87 <0.001 0.08
Diarrhoea 1,605 0.28 0.18, 0.45 <0.001 0.05
Nausea 1,608 1.04 0.76, 1.40 0.82 0.47
Dizziness 1,607 1.50 1.06, 2.11 0.02 0.02
Daytime drowsiness 1,608 0.59 0.41, 0.85 0.005 0.22
Difficulty sleeping 1,605 1.90 1.26, 2.86 0.002 0.19
Hot Flushes 1,606 2.59 1.64, 4.07 <0.001 0.08
Rapid heartbeat 1,607 2.51 1.65, 3.83 <0.001 0.33
Impotence 373 5.21 1.96, 13.85 0.001 0.60
Difficulty ejaculating 344 1.48 0.48, 4.57 0.49 0.80
N Coefficient 95% CI p value p value for interaction between
treatment and time
Number of adverse effects 1,597 0.79 0.48, 1.10 <0.001 0.007
The comparison between the two antidepressants includes all individuals randomly allocated to receive either reboxetine or citalopram. Models are
adjusted for baseline adverse effect, severity of depression and centre. AnORgreater than 1 indicates, that over the 12weeks, the adverse effect was more
commonly reported by individuals randomised to reboxetine than citalopram. A positive coefficient indicates a greater number of adverse effects
reported by individuals randomised to reboxetine than citalopram over the 12 weeks. The interaction reports the p value for the interaction between time
(as a continuous variable) and allocated treatment group
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Table 2 Summary odds ratios or linear regression coefficients reporting the effect of time on adverse effect reporting in a combined analysis, and
stratified by allocated treatment group from a repeated measures analysis at 2, 6 and 12 weeks
Adverse effect Citalopram Reboxetine Combined




OR 95 % CI
Tremor 0.99 0.94, 1.05 0.82 0.93 0.88, 0.99 0.02 0.12 0.96 0.92, 1.00
Agitation 1.01 0.97, 1.05 0.56 0.98 0.94, 1.02 0.35 0.28 1.00 0.97, 1.02
Dry mouth 0.89 0.85, 0.94 <0.001 0.86 0.82, 0.90 <0.001 0.09 0.88 0.85, 0.91
Excessive sweating 1.01 0.97, 1.05 0.68 0.94 0.90, 0.98 0.003 0.02 0.97 0.94, 1.00
Constipation 0.97 0.92, 1.02 0.28 0.91 0.87, 0.95 <0.001 0.08 0.94 0.90, 0.97
Diarrhoea 0.95 0.91, 1.00 0.06 1.04 0.97, 1.11 0.29 0.05 0.98 0.94, 1.02
Nausea 0.97 0.93, 1.01 0.10 0.99 0.95, 1.03 0.56 0.47 0.98 0.95, 1.01
Dizziness 0.96 0.92, 1.00 0.05 0.90 0.86, 0.94 <0.001 0.02 0.93 0.90, 0.95
Daytime drowsiness 1.05 1.01, 1.10 0.02 1.01 0.97, 1.05 0.61 0.22 1.03 1.00, 1.06
Difficulty sleeping 1.01 0.96, 1.06 0.67 0.97 0.93, 1.02 0.19 0.19 0.99 0.96, 1.02
Hot Flushes 0.97 0.93, 1.02 0.29 0.92 0.88, 0.97 0.001 0.08 0.95 0.91, 0.98
Rapid heartbeat 1.06 1.01, 1.11 0.03 1.02 0.98, 1.07 0.33 0.33 1.04 1.00, 1.07
Impotence 0.91 0.81, 1.03 0.15 0.89 0.80, 0.99 0.03 0.60 0.90 0.83, 0.98
Difficulty ejaculating 0.79 0.68, 0.93 0.003 0.85 0.76, 0.96 0.007 0.80 0.83 0.76, 0.91




Coefficient 95 % CI
Number of adverse effects −0.03 −0.06, 0.00 0.1 −0.09 −0.13, −0.05 <0.001 0.007 −0.06 −0.08, −0.03
The summary odd ratios indicate the effect of an increase in time of 1 week on reports of each adverse effect. Models are adjusted for severity of
depression, centre and baseline adverse effect and in the combined analysis, allocated treatment. An OR greater than 1 (or positive coefficient) indicates
that the adverse effect increases with time. The interaction reports the p value for the interaction between time (as a continuous variable) and allocated
treatment group
Table 3 Odds ratios of
discontinuing antidepressant
treatment between 2 and 6 weeks
by adverse effect at 2 weeks
Odds ratios (OR) are estimates
from logistic regression models
with discontinuation from treat-
ment as the outcome. Models are
adjusted for baseline adverse ef-
fect, allocated treatment, severity
of depression and centre. An OR
greater than 1 indicates that the
adverse effect at 2 weeks is asso-
ciated with a higher odds of dis-
continuation from antidepressant
treatment between 2 and 6 weeks.
The interaction reports the p value
for the interaction between ad-
verse effect and allocated treat-
ment group
Adverse effect at 2 weeks N OR 95 % CI p value p value for interaction
between adverse effect
and treatment, p
Tremor 512 1.37 0.73, 2.55 0.32 0.52
Agitation 512 1.47 0.90, 2.41 0.13 0.26
Dry mouth 511 1.00 0.55, 1.79 0.99 0.35
Excessive sweating 512 1.39 0.85, 2.29 0.19 0.71
Constipation 511 1.42 0.85, 2.38 0.19 0.17
Diarrhoea 512 1.25 0.63, 2.45 0.52 0.16
Nausea 512 1.45 0.89, 2.36 0.14 0.12
Dizziness 512 1.83 1.09, 3.09 0.02 0.85
Daytime drowsiness 512 0.69 0.43, 1.12 0.14 0.14
Difficulty sleeping 512 0.86 0.50, 1.48 0.60 0.38
Hot flushes 512 1.51 0.90, 2.51 0.12 0.63
Rapid heartbeat 512 1.12 0.64, 1.98 0.69 0.58
Impotence 121 0.94 0.33, 2.67 0.91 0.71
Difficulty ejaculating 109 1.34 0.48, 3.72 0.58 0.92
Number of adverse effects 510 1.12 1.00, 1.25 0.06 0.63
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We must interpret our results with caution as we were
investigating a total of 14 adverse effects and so are at greater
risk of obtaining type I errors than when investigating a single
exposure. In addition, despite the relatively large sample size,
it is possible that we did not have sufficient power to detect
interactions, which may have resulted in type II errors; how-
ever, we have used the confidence intervals obtained to guide
our interpretation.
A placebo arm was not included in the trial which made
GENPOD more amenable to individuals actively seeking
antidepressant treatment. Therefore, we are limited in only
being able to investigate the differences between the two
antidepressants, a prototypical SSRI and prototypical nor-
adrenaline reuptake blocking antidepressant or NARI. It is
possible that the lack of blinding may have introduced a
source of bias as the participants knew which drug they were
allocated to. However, this would only occur if the partici-
pants had strong preconceptions about the different adverse
effect profiles of citalopram and reboxetine, and so, this is
unlikely to have influenced the results. The GENPOD trial
was also designed to investigate the adverse effect profiles as
one of its secondary outcomes (Thomas et al. 2008).
As has been reported previously (Wiles et al. 2012), due to
the similar scores on depressive scales and similar response
rates to antidepressant treatment seen in other UK depression
trials (Ward et al. 2000; Kessler et al. 2009) and the US
STAR*D study (Trivedi et al. 2006), the GENPOD sample
is a representative of a typical sample of primary care patients
with depression. Additionally, both treatment groups were
allocated antidepressants prescribed at standard doses, and
the GPs retained responsibility for patient care throughout.
Therefore, we suggest that our findings are relevant to other
European and US populations of people with depression.
Comparisons with existing literature
Physical symptoms at baseline
The majority of physical symptoms were more commonly
reported at baseline (medication free) than when actually on
medication. This suggests that our instrument used to record
adverse effects was also measuring active symptoms of depres-
sion. This shows how important it was to include baseline
physical symptoms in our analyses to specifically identify
reports of new physical symptoms (adverse effects). There were
four physical symptoms (dry mouth, constipation, hot flushes
and impotence) reported more frequently at 2 weeks than at
baseline, and more frequently by those allocated to reboxetine
than to citalopram. This suggests that these are specific adverse
effects induced by reboxetine, while other differences in the
adverse effect profile of the two antidepressants might be due to
their differential efficacy in treating specific depressive symp-
toms. High levels of physical symptoms at baseline have been
reported previously, and attempting to distinguish symptoms of
depression from antidepressant-induced adverse effects re-
mains a challenge (Moeller 2001; Uher et al. 2009a, b).
Adverse effect profile
The adverse effect profiles of citalopram and reboxetine have
been well reported and are in general agreement with our
findings in GENPOD (Ferguson 2001a; Hajos et al. 2004;
Langworth et al. 2006). SSRI-induced adverse effects are
thought to occur due to the unwanted stimulation of serotonin
receptors. The majority of serotonin receptors are G-protein
coupled receptors that activate an intracellular messenger
cascade, the exception being the 5-HT3 receptor which is a
ligand-gated ion channel. The 5-HT3 receptor was suggested
to be a possible mediator of SSRI-induced gastrointestinal
adverse effects as 5-HT3 antagonists have been used in the
prevention and treatment of nausea, vomiting and diarrhoea
(Bailey et al. 1995; Thompson 2013). This would explain the
reason why we found evidence that diarrhoea was associated
with citalopram treatment, but not our lack of evidence for an
association with reports of nausea.
The general consensus is that sexual dysfunction is more
commonly reported as an adverse effect induced by SSRI
treatment, potentially due to the stimulation of 5-HT2C recep-
tors (Ferguson 2001b; Morehouse et al. 2011). However, we
report that impotence was more commonly reported by males
allocated to receive reboxetine. Our finding is supported by a
study of 450 depressed individuals randomised to three treat-
ment groups, reboxetine, fluoxetine (an SSRI) or placebo, that
reported a greater number of problems relating to male arous-
al, assessed by dichotomous responses, in the reboxetine
group (Clayton et al. 2003; Schweitzer et al. 2009). The
effects on male arousal may be due to increased levels of
noradrenaline stimulating α1-adrenergic receptors
(Andersson 2011). These receptors are involved in the con-
traction of the corpora cavernosa and penile vessels which
determine the functional state of the penis.
Adverse effects induced by NARIs are likely due to the
stimulation of at least four noradrenergic receptor subtypes in
the brain and body. Increased noradrenergic activity at α1-
adrenergic receptors may produce symptoms indicative of
‘anticholinergic-type’ adverse effects such as dryness of the
mouth and constipation. Reportedly, this is not due to direct
blockade of muscarinic cholinergic receptors but instead, due
to the indirect reduction of net parasympathetic tone due to
increased sympathetic tone, similar to that found in high
arousal states such as public speaking (Gruenberg 2009).
Discontinuation
Regardless of the antidepressant, we found evidence that the
impact of adverse effects on discontinuation was the same. In
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general, there was a tendency towards adverse effects being
associated with higher odds of discontinuation (ie. OR>1).
However, when considering the 95 % CIs, dizziness was the
only adverse effect to be associated with higher odds of
discontinuation. The GENDEP study also reported an associ-
ation between dizziness and discontinuation from antidepres-
sant treatment (Uher et al. 2009a).
Dizziness may have a greater impact on daily routine (that
is, on driving) than other adverse effects which may explain
why we found evidence of an association with discontinua-
tion. The cause of antidepressant-induced dizziness is not
known; in the case of reboxetine, it might be postural hypo-
tension from altered baroreceptor function as found with other
noradrenaline-acting TCA antidepressant imipramine
(Middleton et al. 1988). SSRI-induced dizziness is much less
explored but may reflect a direct effect on the inner ear.
Informing patients of potential adverse effects prior to starting
a new medication improves patients’ knowledge of potential
risks and does not lead to an increased incidence of those
adverse effects (Lamb et al. 1994; Krska andMorecroft 2013).
Therefore, adherence may improve if patients are specifically
warned about, and given advice on how best to deal with,
antidepressant-induced dizziness (that is, avoid standing up
quickly).
Although the majority of adverse effects were not associ-
ated with discontinuation, there was some evidence of an
association with the number of adverse effects reported. This
suggests that the overall burden of adverse effects may be
more important to tolerability than the majority of individual
adverse effects. Additionally, the majority of individuals who
discontinued antidepressant treatment cited adverse effects as
the reason why. If this is the case, then reducing any adverse
effect which is easily treatable may increase adherence. We
acknowledge that other adverse effects not recorded at 2weeks
in this study may have an important role in discontinuation of
antidepressant treatment—especially urinary problems and
blurred vision, which have previously been associated with
antidepressant discontinuation (Uher et al. 2009a).
There was a suggestion that four adverse effects (constipa-
tion, diarrhoea, nausea and drowsiness) may have a different
impact on discontinuation between the treatment groups (p
value for interaction between allocated treatment and adverse
effect is <0.20). In the citalopram group, individuals reporting
constipation or nausea had over twice the odds of
discontinuing by 6 weeks. Conversely, individuals reporting
drowsiness had a 60 % lower odds of discontinuing treatment
from citalopram. The routine collection of discontinuation and
adverse effect data that is now required for all RCTs will
enable us to clarify the role these adverse effects may have
in antidepressant discontinuation.
It appears that adverse effects induced by SSRIs or NARIs
are only one factor important in treatment adherence. This is
supported by a previous study of 265 depressed individuals
receiving an SSRI which reported no evidence of an associa-
tion between any single adverse effects, or overall adverse
effect rating, with discontinuation (Warden et al. 2010).
Adverse effects over time
Previous studies and the BAP guidelines have reported that
adverse effects tend to subside with time (Masand 2003;
Anderson et al. 2008; Uher et al. 2009a). This may be due to
the desensitisation of receptors that cause the adverse effects
(Nutt and Glue 1991). Reports of half of the adverse effects,
and the number of adverse effects reported, reduced between 2
and 12 weeks for both antidepressants. Additionally, all ad-
verse effects, except diarrhoea, were reported less frequently
at 12 weeks than at 6 weeks. Our results were not substantially
different when we restricted our analysis to include only those
who adhered to treatment. Therefore, the reduction in adverse
effect reporting is not just due to fewer people taking the
medication as the trial progressed.
Reports of diarrhoea tended to persist throughout the
12 weeks for individuals receiving reboxetine. Diarrhoea is
regarded as a typical SSRI adverse effect and was reported
much more frequently by individuals receiving citalopram in
our study. Reports of diarrhoea from individuals receiving
reboxetine may represent a physical symptom of depression
rather than an adverse effect induced by reboxetine. The same
may be true for individuals receiving citalopram and reporting
sweating, a commonly reported adverse effect of NARIs,
throughout the 12 weeks. Each physical symptom reported
throughout the trial is likely due to a combination of being
both a symptom of depression and an adverse effect.
Several of the adverse effects were reported less frequently
at 2 weeks than at 6 weeks. Previous reports have suggested
that the mode of administration does not introduce any bias, at
least for mental health assessments (Evans et al. 2004).
However, it is possible that the different methods of data
collection at these two time points may explain this result.
Alternatively, if these findings are replicated, it may encour-
age patients to know that after 6 weeks of treatment, reports of
these adverse effects tend to reduce.
Implications and further research
The GENPOD study has allowed a detailed comparison be-
tween two pharmacologically different antidepressants,
citalopram and reboxetine. Antidepressant-induced dizziness
as well as the total number of adverse effects reported ap-
peared to be important factors in discontinuation from antide-
pressant treatment. Greater information on the time course of
specific physical symptoms will allow doctors to inform pa-
tients more clearly on the adverse effects they can expect
throughout the duration of antidepressant treatment which
may lead to greater adherence to treatment (Frank and Judge
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2001; Lingam and Scott 2002). This has obvious and impor-
tant clinical implications as individuals who discontinue anti-
depressant treatment prematurely may not benefit from treat-
ment and are at a higher risk of relapse (Montgomery et al.
1993; Donoghue et al. 1996).
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